Genomic Valley Biotech Q2 Results Total Revenue Climbs to ₹21.22 Crores

Genomic Valley Biotech Q2 Results

Genomic Valley Biotech Q2 Results: The Genomic Valley Biotech data table presents financial results over different time periods, allowing us to see how the company is performing. In the most recent three months ending on September 30, 2024, the company earned ₹20,50,000 from its operations, which is a significant increase compared to the previous three months (June 30, 2024), where it earned ₹15,53,350. Looking back to the same period last year (September 30, 2023), the revenue was much lower at ₹6,75,250, showing that the company has grown a lot over the year.

Genomic Valley Biotech’s Total revenue, which includes both operational earnings and other income, reached ₹21,22,187 during this recent quarter. The company's expenses were ₹6,46,550, covering costs like employee salaries and other operational expenses. Despite these expenses, the profit before tax was a healthy ₹14,75,637, showing that the company is managing its costs well while increasing revenue.

Genomic Valley Biotech’s Year-to-date figures also reflect strong performance, with total revenue for the year so far being ₹36,75,537. Overall, Genomic Valley Biotech appears to be on a positive trend, demonstrating significant growth in both revenue and profit compared to previous periods. This indicates the company's strong position in the biotech industry.

Here’s the financial results data presented in a simple table format:

(Figures in INR)

Source: Here 

For More Q1 Results check our Twitter Page

Visit our website for more Q1 results

Genomic Valley Biotech Financial Metrics

Genomic Valley Biotech is a company that focuses on biotechnology, which involves using living organisms or their systems to develop products and technologies. The company has a market capitalization of ₹26.1 crore, meaning it is valued at this amount in the stock market. Its current share price is ₹85.4, which is the price for buying one share of the company. The stock has a high of ₹85.4 and a low of ₹21.0, showing its price fluctuations. The price-to-earnings ratio (P/E) is 100, indicating the market values its shares highly compared to its earnings.

Here’s the information you provided in a clear and organized table format:

Quarterly Results 

The Genomic Valley Biotech data table shows financial results over several quarters, specifically focusing on three quarters: March 2024, June 2024, and September 2024. In March 2024, the company had no sales and a slight loss of Rs. 0.04 crores in operating profit. However, by June 2024, sales increased to Rs. 0.16 crores, leading to a positive operating profit of Rs. 0.13 crores. By September 2024, sales further improved to Rs. 0.21 crores, and the operating profit rose slightly to Rs. 0.14 crores. 

Here’s the quarterly results for Mar 2024, Jun 2024, and Sep 2024:

(Figures in Rs. Crores)

About Genomic Valley Biotech

Genomic Valley Biotech is a healthcare company focused on using advanced technology to improve patient care. The team at Genomic Valley has over 10 years of experience in important areas like Next-Generation Sequencing (NGS), cancer research (oncology), and Artificial Intelligence (AI). They are dedicated to creating better tools and methods for diagnosing and treating diseases. Inspired by former Prime Minister Atal Bihari Vajpayee, the company aims to build a “Silicon Valley of genomics” in India, making it a global center for genomic research and healthcare solutions.

Genomic Valley's mission is to make medical testing faster and more accurate. They want to help doctors provide personalized treatments by using data and technology. By combining AI with healthcare, Genomic Valley is changing the way doctors understand and treat cancer, ensuring patients get the best care possible.

In addition to its research and diagnostics, Genomic Valley offers services to support researchers worldwide. They provide expert help and access to advanced tools to improve research quality. Overall, Genomic Valley Biotech is committed to innovation and excellence in healthcare, working towards a healthier future for everyone.